Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | RELA | Q04206 | 4/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3726073 | 0.86 | RELA (0.47) | CA1RELAPPARACA2CA12 | |
| SCHEMBL11515763 | 0.84 | CA1 (0.55) | CA1RELAPPARACA2CA12 | |
| SCHEMBL5689488 | 0.82 | CA1 (0.52) | CA1RELAPPARACA2CA12 | |
| SCHEMBL4813487 | 0.81 | CA1 (0.46) | CA1RELAPPARACA2CA12 | |
| SCHEMBL4998398 | 0.80 | RELA (0.58) | CA1RELAPPARACA2CA12 | |
| SCHEMBL14081786 | 0.78 | RELA (0.61) | CA1RELAPPARACA2CA12 | |
| SCHEMBL7689617 | 0.78 | RELA (0.61) | CA1RELAPPARACA2CA12 | |
| SCHEMBL1155970 | 0.77 | CA1 (0.57) | CA1RELAPPARACA2CA12 | |
| SCHEMBL6827393 | 0.77 | CA1 (0.46) | CA1RELAPPARACA2CA12 | |
| SCHEMBL27026966 | 0.77 | CA1 (0.46) | CA1RELAPPARACA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1603885-A1 | FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004080973-A1 | FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | CA1 2163/4885RELA 3214/4885PPARA 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.